Clinical Report: COVID-19 Financial Burdens in Renal Cell Carcinoma Patients
Overview
A survey of 539 renal cell carcinoma patients revealed significant financial toxicity exacerbated by the COVID-19 pandemic, with lower-income patients experiencing higher anxiety about financial hardship. The median COST score indicated moderate financial distress, particularly among metastatic patients not yet on systemic therapy.
Background
The COVID-19 pandemic has strained healthcare systems globally, prompting changes in cancer care delivery to reduce patient exposure and preserve resources. Renal cell carcinoma treatment advances have improved survival but coincided with increased patient cost-sharing, raising concerns about financial toxicity. Economic impacts of the pandemic threaten patients' ability to afford care, potentially influencing outcomes. This study surveyed renal cell carcinoma patients to assess anxiety related to COVID-19 and financial burden.
Data Highlights
Characteristic
Value
Total respondents
539
Metastatic disease
52% (280 patients)
Median age
55 years (range 24–87)
Female
58%
White
88%
Household income $50,000–$99,999
30%
Household income >$100,000
38%
Median COST score (all patients)
21.5 (range 1–44)
Median COST score metastatic, no systemic therapy
19.8 (range 2–41)
Median COST score systemic oral therapy
23.9 (range 4–44)
Median COST score post-surgery follow-up
20.8 (range 1–40)
Key Findings
59% of patients worried savings or retirement assets would not cover treatment costs.
26% feared job and income loss due to the pandemic.
Patients with income < $50,000 reported significantly higher financial anxiety than those with income > $100,000 (93% vs 82%, p < 0.001).
Only 8% of patients felt confident about their financial situation.
Higher anxiety about COVID-19 correlated with expectations of medical, behavioral, and psychological hardship (p < 0.001).
Metastatic patients not on systemic therapy had the lowest median COST scores, indicating worse financial toxicity.
Clinical Implications
Clinicians should recognize the heightened financial distress among renal cell carcinoma patients during the COVID-19 pandemic, especially in lower-income groups. Incorporating financial counseling and support services into cancer care may mitigate treatment-related financial toxicity. Awareness of patients' anxiety related to both COVID-19 and financial hardship can guide holistic care planning.
Conclusion
The COVID-19 pandemic has intensified financial toxicity in renal cell carcinoma patients, disproportionately affecting those with lower income and metastatic disease. Addressing these burdens is critical to ensuring equitable access to cancer care and optimizing patient outcomes.
References
Kidney Cancer Research Alliance Survey Data 2020 -- The Impact of COVID-19 on Financial Burdens in Renal Cell Carcinoma Patients
CAR T-cell therapies are the future of cancer treatment and Roswell Park Comprehensive Cancer Center is preparing to open a number of new trials based on research originating here and in partnership with the industry.
